Business
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations - - Time Course of MRI Lesion Suppression Shows
About this update from Immunic, Inc.
[{"type":"text","content":"- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -\n - Time Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan at Week 6, Validating Rapid Attainment of Stable Therapeutic Drug Levels of IMU-838 -\n - A Robust Decrease in Serum Neurofilament Light Chain, A Biomarker for Axonal Damage, Was Observed in Both Treatment Arms of IMU-838 But Not in the Placebo Arm -\n - Poster, Including Audio Track, With Summary of Full Data Set, to be Presented Online at the MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting by Robert J. Fox, M.D. -\n - Conference Call and Webcast to Review the Full Unblinded EMPhASIS Data to be Held September 14, 2020 at 8:00 am ET -\n\n\nNEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the full unblinded clinical data set from the company's phase 2 EMPhASIS trial of lead asset, IMU-838, a selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS) is now available and expands on and confirms the company's previously announced positive top-line results. A summary will be presented at the MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting, taking place September 11-13, 2020, online, by Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio.\nAbstract Title: Top-line Results of EMPhASIS, a Phase 2 Clinical Trial of Vidofludimus Calcium (IMU-838) in Relapsing-Remitting Multiple SclerosisAbstract Number: 1409Poster Number: P0241\nThe poster presentation, including Dr. Fox's audio track, will be published today at 8:00 am ET in the MSVirtual2020 E-Poster Hall. Dr. Fox's poster presentation as well as the full unblinded EMPhASIS data will be filed on Form 8-K today, before the opening of the U.S. financial markets, and will be accessible on the \"Events and Presentations\" section of Immunic's website at: ir.imux.com/events-and-presentations.\n\"The results from the phase 2 study of IMU-838 in patients with RRMS are encouraging, as the data show that the trial has met i...